A hepatitis C genotype is a classification based on the genetic makeup of the specific strain of hepatitis C virus (HCV) infecting a person. There are seven confirmed major genotypes, numbered 1 through 7, and at least 67 subtypes within them. These genetic differences matter because they influence how the virus behaves in the body, where it’s most commonly found in the world, and in some cases, how it responds to treatment.
How Genotypes Are Classified
Hepatitis C is an RNA virus, meaning its genetic code is stored in a molecule called RNA rather than DNA. Over thousands of years, the virus has evolved into genetically distinct lineages. Two strains are considered separate genotypes when their genetic sequences differ substantially across the full viral genome. Within each genotype, subtypes are labeled with letters (1a, 1b, 3a, and so on) and must differ from other subtypes by at least 15% of their nucleotide positions to qualify as distinct.
The classification system is built on phylogenetic analysis, which maps evolutionary relationships between viral strains by comparing their genetic code. To be officially recognized, a new subtype needs complete genome sequences from at least three unrelated cases, and scientists must rule out that the apparent differences are simply the result of two genotypes swapping genetic material with each other.
The Seven Genotypes and Where They’re Found
Genotype 1 is by far the most common worldwide, responsible for about 49% of all hepatitis C infections. Genotype 3 accounts for roughly 18%, genotype 4 for about 17%, and genotype 2 for 11%. Genotypes 5 and 6 together make up less than 5% of global cases.
The distribution varies dramatically by region. In the Americas, genotype 1 dominates at nearly 75% of infections. Europe follows a similar pattern, with genotype 1 at 64% and genotype 3 at 26%. In Africa, the picture is more mixed: genotype 4 leads at 28%, followed closely by genotypes 1 and 2 at around 26% and 24%, respectively. Genotype 5 is almost exclusively found in Africa, where it accounts for 12% of cases. In Asia, genotype 6 has a notable presence at 7%, while genotypes 1 and 3 are most common.
Genotypes 7 and 8 are rare. Genotype 7 has been identified in a small number of people from the Democratic Republic of Congo and Uganda. Genotype 8 was first found in patients originally from the Punjab region of India living in Canada or Australia, with additional cases identified in people of Indian and Pakistani heritage in the United Kingdom. Researchers have even proposed the existence of a genotype 9, though this hasn’t been formally confirmed.
Why Genotype 3 Is Considered More Aggressive
Not all genotypes behave the same way in the body, and genotype 3 stands out as particularly concerning. It’s associated with higher rates of fatty liver (steatosis) through mechanisms specific to that genotype, not just the general liver inflammation that all HCV strains cause. A large analysis of over 1,100 patients in Switzerland found that genotype 3 was independently linked to more advanced liver scarring. A separate meta-analysis of more than 2,300 patients confirmed this, finding that genotype 3 carried roughly 1.5 times the odds of accelerated scarring progression compared to other genotypes.
Genotype 3 is also associated with higher rates of liver cancer. Even after successful treatment that clears the virus, people who had genotype 3 face elevated liver cancer risk, likely because their liver disease had already progressed further before treatment.
How Genotype Affects Treatment
For most of HCV treatment history, knowing the genotype was essential because different drug combinations worked better or worse depending on the strain. That changed with the development of pangenotypic direct-acting antivirals, which target the virus regardless of genotype. These treatments, typically taken as daily pills for 8 to 12 weeks, achieve cure rates above 94% for genotypes 1, 2, and 4.
Genotype 3 remains the hardest to treat. Cure rates for genotype 3 with pangenotypic regimens sit around 89%, still high but noticeably lower, with wider variability between studies. The World Health Organization defines a pangenotypic regimen as one that cures more than 85% of patients across all six major genotypes, and genotype 3 is the strain that tests that threshold most closely.
Even the rare genotypes respond well to modern treatment. All reported cases of genotype 8 infections treated with pangenotypic drugs achieved a cure, despite the virus carrying genetic mutations that might have suggested resistance.
Do You Still Need Genotype Testing?
Current U.S. treatment guidelines no longer require genotype testing before starting treatment for every patient. If you have no cirrhosis and have never been treated before, your doctor can prescribe a pangenotypic regimen without knowing your genotype. This simplifies care and removes a potential barrier to getting started on treatment.
Genotyping is still recommended in two situations: if you have cirrhosis, or if you’ve been treated for hepatitis C before and it wasn’t cured. In both cases, the treatment approach may differ depending on which genotype you carry, so testing helps your doctor choose the most effective regimen.
How Genotype Testing Works
Genotype testing is done on a blood sample. The lab isolates the virus’s genetic material and identifies the genotype using one of several techniques. The most common approach involves sequencing specific conserved regions of the viral genome, essentially reading out the genetic code and matching it against known genotype sequences. Commercial kits can identify genotypes 1 through 6 from a single blood draw, and some can further distinguish between subtypes like 1a and 1b.
Other methods use specially designed genetic probes that bind only to specific genotypes, or amplify the viral genetic material and analyze how it behaves under heating (a technique called melting curve analysis). Fully automated systems can now handle the entire process from sample to result. These tests are widely available in high-income countries, though access remains a challenge in parts of the world where hepatitis C is most prevalent.
Genotype 1 Subtypes: 1a vs. 1b
Because genotype 1 is so common, its two main subtypes deserve attention. Subtype 1b is more prevalent globally and tends to appear in older patients, while 1a is more common in younger people, particularly men. In one large Italian study, 1a patients were younger, more often male, and had less advanced liver scarring, suggesting that subtype 1a spread more recently in that population.
With older interferon-based treatments, both subtypes responded similarly, with cure rates of 45% for 1a and 37% for 1b, a difference that wasn’t statistically significant. With modern direct-acting antivirals, both subtypes are highly curable. The distinction between 1a and 1b can still matter in specific treatment decisions, particularly when selecting certain drug combinations that may have slightly different resistance profiles for each subtype.